Compliance Rate
Compliance Rate
0%
Compliant submissions
0
Incompliant submissions
0
Total trials
0
My Organizations' Clinical Trials
Showing 4 of 4 entries
View as:
Phase: N/A
Priority: Normal
Start: 12/01/20
End: 03/26/25
Due: 03/26/26
Phase: N/A
Priority: Normal
Start: 10/08/18
End: 08/11/20
Due: 08/11/21
Phase: N/A
Priority: Normal
Start: 05/04/18
End: 02/05/21
Due: 02/05/22
Phase: N/A
Priority: Normal
Start: 10/31/16
End: 05/31/20
Due: 05/31/21
| Title | NCT ID | Organization | User | Status | Start Date | End Date | Reporting Due Date | Last Checked | User Role | Org Created |
|---|---|---|---|---|---|---|---|---|---|---|
| A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma | NCT04625205 | BioNTech US Inc. | user2@example.com | None | 2020-12-01 | 2025-03-26 | 2026-03-26 | - | - | 2025-07-14 |
| A Personal Cancer Vaccine (NEO-PV-01) and APX005M or Ipilimumab With Nivolumab in Patients With Advanced Melanoma | NCT03597282 | BioNTech US Inc. | user2@example.com | None | 2018-10-08 | 2020-08-11 | 2021-08-11 | - | - | 2025-07-14 |
| A Personal Cancer Vaccine (NEO-PV-01) With Pembrolizumab and Chemotherapy for Patients With Lung Cancer | NCT03380871 | BioNTech US Inc. | user2@example.com | None | 2018-05-04 | 2021-02-05 | 2022-02-05 | - | - | 2025-07-14 |
| A Personal Cancer Vaccine (NEO-PV-01) w/ Nivolumab for Patients With Melanoma, Lung Cancer or Bladder Cancer | NCT02897765 | BioNTech US Inc. | user2@example.com | None | 2016-10-31 | 2020-05-31 | 2021-05-31 | - | - | 2025-07-14 |